Pharmacological Inhibition of FKBP51 Mitigates Early Life Adversity-Induced Social Deficits
Authors:
- Joeri BordesJBJoeri Bordes
- Xiuqi JiXJXiuqi Ji
- Serena GasperoniSGSerena Gasperoni
- Choham Sudre-ChinskyCSChoham Sudre-Chinsky
- Daniela HarbichDHDaniela Harbich
- Cornelia FlachskammCFCornelia Flachskamm
- Paula FontanetPFPaula Fontanet
- Sowmya NarayanSNSowmya Narayan
- Manfred UhrMUManfred Uhr
- Christian NamendorfCNChristian Namendorf
- Alon ChenACAlon Chen
- Felix HauschFHFelix Hausch
Preprint
Abstract
Early life adversity (ELA) is a major risk factor for psychiatric disorders, but targeted preventative strategies are lacking due to poor mechanistic insight. The FKBP51 protein, a co-chaperone of the glucocorticoid receptor, is a key mediator of stress vulnerability. We tested if pharmacological inhibition of FKBP51 with the selective inhibitor SAFit2 prevents the long-term consequences of ELA. Mice exposed to ELA exhibited persistent deficits in social behavior, manifesting as social subordination in adolescence and adulthood. Early-life SAFit2 treatment fully rescued these ELA-induced behavioral impairments. Transcriptional profiling across six stress-relevant brain regions revealed that SAFit2 normalized ELA-driven gene expression changes, particularly in the medial prefrontal cortex and nucleus accumbens. Functional analysis showed the rescue converged on immunoregulatory and neuroactive ligand-receptor signaling pathways. Our findings establish FKBP51 as a critical pharmacological target for reversing the lasting impact of early life adversity on brain function, offering a path toward preventative treatment for ELA-related psychopathology.Keywords
Funding Information
- Federal Ministry of Education and Research Germany (01GL1743C)
- Swedish Society for Medical Research
- Swedish brain foundation
- Strategic Research Area Neuroscience
This publication has 48 references indexed in Scilit:
- The evolving neurobiology of early-life stressNeuron, 2025
- The role of Toll‐like receptors in neuropsychiatric disorders: Immunopathology, treatment, and managementMedicinal Research Reviews, 2024
- Advancing social behavioral neuroscience by integrating ethology and comparative psychology methods through machine learningNeuroscience & Biobehavioral Reviews, 2023
- Genetically engineered mouse models of FK506‐binding protein 5Journal of Cellular Biochemistry, 2023
- Associations of psychiatric disease and ageing with FKBP5 expression converge on superficial layer neurons of the neocortexActa Neuropathologica, 2023
- Focus on FKBP51: A molecular link between stress and metabolic disordersMolecular Metabolism, 2019
- Vesicular phospholipid gels as drug delivery systems for small molecular weight drugs, peptides and proteins: State of the art reviewInternational Journal of Pharmaceutics, 2019
- GxE effects of FKBP5 and traumatic life events on PTSD: A meta-analysisJournal of Affective Disorders, 2019
- Association of FKBP5 Polymorphisms and Childhood Abuse With Risk of Posttraumatic Stress Disorder Symptoms in AdultsJAMA, 2008
- Stress, genes and the mechanism of programming the brain for later lifeNeuroscience & Biobehavioral Reviews, 2005